IGF2-induced BACH1 upregulated cancer progression-associated genes IGF1R and PTK2. IGF1R blockade combined with PTK2 inhibition enhanced HCC therapeutic efficacy. This evidence concerns the gene IGF2 and hepatocellular carcinoma.